. Author manuscript; available in PMC: 2019 Jul 1.

Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2018 May 16;27(7):728–736. doi: 10.1158/1055-9965.EPI-17-0573

TABLE 2.

Prognostic and predictive biomarker analysis for pretreatment adenoma Cox-2 and 15-PGDH determination

Prognostic biomarker assessment: Patients receiving placebo
Biomarker result	No. at risk	3-year cumulative adenoma incidence (SE)	Risk Ratio (95% confidence interval)	p-value
15-PGDH present	52	51.5% (7.2)	1.20 (0.87, 1.65)	0.25
15-PGDH absent	388	63.3% (2.5)	1.20 (0.87, 1.65)	0.25
Cox-2 high	28	70.5% (9.2)	0.78 (0.57, 1.08)	0.18
Cox-2 low	412	61.4% (2.5)	0.78 (0.57, 1.08)	0.18

Predictive biomarker assessment: All patients
Biomarker result	No. at risk	3-year cumulative adenoma incidence %(SE)	Risk Ratio (95% confidence interval)	p-value		No. at risk	3-year cumulative adenoma incidence %(SE)	Risk Ratio (95% confidence interval)	p-value
15-PGDH present					15-PGDH absent
Placebo	52	51.5 (7.2)	0.73 (0.47, 1.12)	0.15	Placebo	388	63.3 (2.5)	0.60 (0.52,0.69)	<0.0001
Celecoxib	87	42.4 (5.8)	0.73 (0.47, 1.12)	0.15	Celecoxib	768	41.9 (1.9)	0.60 (0.52,0.69)	<0.0001
Cox-2 high					Cox-2 low
Placebo	28	70.5 (9.2)	0.37 (0.22,0.61)	0.0001	Placebo	412	61.4 (2.5)	0.64 (0.56,0.73)	<0.0001
Celecoxib	78	34.1 (5.8)	0.37 (0.22,0.61)	0.0001	Celecoxib	777	42.7 (1.9)	0.64 (0.56,0.73)	<0.0001